Retatrutide: Is the 'Triple-G' Peptide Really the Next Ozempic?

If you've followed the rise of Ozempic and Mounjaro, you've probably seen the next name already generating headlines: retatrutide, often nicknamed the "triple-G" or "King Kong" peptide. The trial numbers are genuinely eye-catching — weight loss large enough to make experienced researchers sit up. But "eye-catching phase 2 result" and "safe, approved medicine you can get" are two very different things, and the gap between them is exactly what this article is about. If you're new to this whole class of drugs, our guide to weight-loss peptides is the place to start; this is the deeper dive on the newest one.

What is retatrutide?

Retatrutide (development code LY3437943) is an injectable peptide being developed by Eli Lilly. What makes it different is how many targets it hits at once. Your gut releases hormones after eating that influence appetite, blood sugar and metabolism. The current drugs work by mimicking these hormones:

• Semaglutide (Ozempic, Wegovy) activates one receptor: GLP-1.
• Tirzepatide (Mounjaro, Zepbound) activates two: GLP-1 and GIP.
• Retatrutide activates three: GLP-1, GIP and glucagon.

That third target — the glucagon receptor — is the novelty. Glucagon is best known for raising blood sugar, but it also increases energy expenditure and can reduce fat in the liver. The idea behind retatrutide is that adding glucagon's "burn" to the appetite- suppressing effects of GLP-1 and GIP could do more than either of the existing drugs ¹.

What did the trials actually show?

This is where retatrutide earned its reputation, and the headline numbers are real.

In a 48-week phase 2 trial published in the New England Journal of Medicine in 2023, adults with obesity who took the highest dose (12 mg weekly) lost on average about 24% of their body weight — roughly a quarter of their starting weight — and the curve hadn't clearly flattened by the end, suggesting more might have followed ¹. For context, that's larger than the average seen in the headline semaglutide and tirzepatide obesity trials. A separate phase 2 trial in people with type 2 diabetes, published in The Lancet, showed strong improvements in blood sugar and body fat ², and an early phase 2a study in fatty liver disease (MASLD) reported large reductions in liver fat ³.

Three honest caveats sit underneath those numbers:

• These are phase 2 trials. Mid-stage studies are designed to find a promising dose and check safety signals — not to be the final word. Drugs that look dazzling at phase 2 can disappoint or reveal problems in larger, longer phase 3 trials.
• Cross-trial comparisons are not head-to-head. Saying retatrutide "beats" Ozempic on weight means comparing different studies with different patients — suggestive, not proof. Only a direct trial settles that, and our Ozempic vs Mounjaro explainer shows why those comparisons need caution.
• The big phase 3 programme is still reporting. The pivotal TRIUMPH trials — thousands of people, longer follow-up — are what regulators will judge.

Is it approved? Can you get it?

As of 2026, retatrutide is not approved by the FDA, the EMA or any major regulator. It remains an investigational drug, available legitimately only inside clinical trials. That matters enormously for one reason: anything currently sold online as "retatrutide" is not the trial drug. It's an unapproved, unregulated grey-market product of unknown purity, sterility and dose — the same sourcing problem we describe for research peptides generally, but with a molecule powerful enough that getting the dose wrong matters more, not less. Self-experimenting with an injectable that researchers are still carefully dose-finding is exactly the scenario the trial process exists to prevent.

What about side effects?

Retatrutide's side-effect profile in the trials looked like the rest of its drug class: mostly gastrointestinal — nausea, diarrhoea, vomiting and constipation — generally worse when starting or stepping up the dose ¹. Because glucagon can raise heart rate and influence blood sugar, those are specific things the longer trials are watching closely. And as with any drug that drives fast, large weight loss, the familiar trade-offs apply: muscle loss alongside fat, and the cosmetic facial changes people call "Ozempic face". The crucial unknown is simply time — these drugs are meant to be taken for years, and the multi-year safety record that only accumulates with use isn't in yet.

What we see at the clinic

Retatrutide comes up now in almost every conversation about weight-loss medication — usually someone who's read the "24%" figure and wants to know where to get it. We give the same honest answer every time: the science is genuinely exciting, but it's still experimental and not approved, and what's sold under that name online isn't the studied drug. For people who are serious about metabolic health, the productive conversation isn't about chasing the newest molecule — it's about whether an approved medication fits, alongside the unglamorous foundations (nutrition, muscle-preserving activity, sleep and honest blood-sugar tracking) that make any of these drugs work better and that don't reverse the moment you stop.

Common questions

Is retatrutide better than Ozempic or Mounjaro? Its phase 2 weight-loss numbers were higher, but those come from separate trials, not direct comparisons — and it hasn't finished phase 3. It's promising, not proven superior ¹.

Can I buy retatrutide legally? Not as an approved medicine — it isn't one yet. Anything sold online as "retatrutide" is an unregulated research chemical of unknown contents, not the trial drug.

What does the third hormone, glucagon, add? In theory it raises energy expenditure and reduces liver fat on top of the appetite effects of GLP-1 and GIP ³. In practice, more targets also means more to monitor — which is why long trials matter.

When might it actually be available? That depends on the phase 3 TRIUMPH results and regulators, which can take years and sometimes don't end in approval. There's no reliable date, and anyone promising one is guessing.

Key takeaway

Retatrutide is one of the most promising obesity and metabolic drugs in development — its triple-receptor design produced some of the largest trial weight-loss figures yet seen. But "promising in phase 2" is not "proven and approved", and it isn't either of those yet. The version sold online today is an unregulated unknown, not the trial drug. If and when it clears phase 3 and regulators, it could be a genuine step forward; until then, the sensible path runs through approved options and the basics, guided by a physician — not a grey-market vial.